|
Recipients of donation after circulatory determination of death (DCDD) liver transplants historically have an increased risk of graft failure. Antibody induction (AI) with anti‐thymocyte globulin (ATG) or anti‐IL2 receptor (anti‐IL‐2R) immunotherapy may decrease the incidence of graft failure by mitigating ischemia reperfusion injury.
|